Vidac Pharma CEO to Present at 19th Annual European Life Sciences CEO Forum

Vidac Pharma Holding PLC announced that its chairman and chief executive officer will present at the 19th Annual European Life Sciences CEO Forum, organized by Sachs Associates. The conference will be held on March 4–5, 2026, at the Hilton Zurich Airport Hotel. The executive will deliver a 20-minute presentation, including a question-and-answer session, on March 4, 2026, at 14:40 (Track C, Room Berne).

During the presentation, the CEO will provide an update on the company's recent progress, including clinical advancements, strategic developments, and the continued expansion of Vidac's oncology pipeline. "We look forward to presenting Vidac's recent progress at the European Life Sciences CEO Forum and to engaging with the international investment and healthcare community," the CEO stated. The forum, hosted annually by Sachs Associates, brings together senior executives from biotechnology and pharmaceutical companies with global institutional investors and strategic partners.

Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines for oncologic and onco-dermatologic diseases. The company's approach targets the overexpression and mislocalization of the Hexokinase-2 (HK2) metabolic checkpoint in cancer cells to renormalize the tumor microenvironment. Vidac's lead drug candidate, VDA-1102, has demonstrated efficacy against advanced Actinic Keratosis in Phase 2b studies and positive results in Cutaneous T-cell Lymphoma in a Phase 2A trial.